Professional Documents
Culture Documents
TESTING
Stability : time period in which the drug product retains the same properties
and characteristics that it possessed at the time of its manufacturing.
Regulatory perspective:
FDA guidance
states
Starting early in
The results should
In phase III of preclinical phase or
be summarized and
regulatory phase I of clinical
submitted in an
submission process. trials is highly
annual report.
encouraged
Factors that influence photostability
8
of drug products
Particle size
Drug content
Tablet geometry
Preparation method
Concentration
pH and Ionization
Ionic strength
Oxidation
Some typical examples of
9
photostability studies of drugs
Carbamazepine : polymorphs in
solid dosage form (tablets),
surface discoloured to yellow and
then orange with results
indicating polymorph II to be the
least stable.
Cyanocobalamin : photolysis in
the presence of visible light at
various pH, confirmed that
protonated form was more
susceptible to photolysis.
Furosemide : forms
sulphamoylanthranilic acid after
exposure to sunlight.
Pharmaceutical Product sensitivity
10
Classification
PHOTOSTABLITY
TESTING OF NEW
DRUG SUBSTANCES
AND PRODUCTS AS
PER
ICH Q1B
GUIDELINE
11
The guideline
Alternative
The guideline is does not cover
approaches may
for photostability the photostability
be used if they
information for of drugs after
are scientifically
Registration for administration
sound and
new molecular (i.e. under
justification is
entities. conditions of
provided.
use).
12
The intrinsic
photostability
characteristics of
Studies should be
new drug
repeated if certain
substances and
Normally, carried variations and
products should be
out on a single changes are made
evaluated to
batch of material. to the product (e.g.,
demonstrate light
formulation,
exposure does not
packaging).
result in
unacceptable
change.
13
LIGHT SOURCES
14
Option 1
Any light source that is designed to
produce an output similar to the D65/ID65*
emission standard such as
an artificial daylight
fluorescent lamp metal halide
combining visible xenon
and ultraviolet (UV) lamp.
outputs
*D65 is the internationally recognized standard for outdoor daylight as
defined in ISO 10977 (1993). ID65 is the equivalent indoor indirect daylight
standard.
LIGHT SOURCES
16
Option 2
Similar sample should be exposed
to both the cool white fluorescent
and near ultraviolet lamp.
Tests on the
Tests on the A systematic exposed drug
drug product approach to product
in the
photostability outside of the
marketing
immediate
pack testing pack
Tests on the
drug product in
the immediate
pack
19
DRUG SUBSTANCE
20
Forced degradation
testing
Consist of two
parts:
Confirmatory
testing.
31
1. Troublesome Lamp Selection
32
Xenon and metal halide lamps have a short life span and need
replaced every 750 to 1500 hours.
Require light filters to eliminate radiation below 320nm.
They also have a relatively small illumination area.
2. Irradiance Measurement Difficulty
34
38
1. Prudent Lamp Selection
Option II of ICH guidelines (cool white and near- UV fluorescent lighting)
• Independent control of illuminance and UVA irradiance eliminates overexposure.
• Fluorescent lamps generate minimal heat.
• Eliminate the need for expensive light filters and dark controls.
• Small internal fans can be employed to subtly maintain proper air temperature
without disturbing sample presentation.
• Typically last over ten thousand hours, have low replacement costs, and provide a
large illumination area.
40
Sliding shelves, access ports and security lockouts are other features that can
CONCLUSION
41
For blisters, which are not light protective, store blister in carton.
If product is not light stable; label should state that protect form
light and container should be light protective; light transmission
CONCLUSION
42